HaemaLogiX
Updated: February 23, 2026
CEO Chris Baldwin
Country: Australia | Funding: A$10M (+)
Founded: 2014
Website: https://haemalogix.com/
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
Founded: 2014
Website: https://haemalogix.com/
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
